Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

Summary

The purpose of this antidepressant study is to determine the efficacy of vortioxetine on depression and cognition in 80 women with breast cancer, and to elucidate inflammatory-mediated mechanisms by which depression and its treatment influence cancer outcome. Our hypothesis is that effective vortioxetine antidepressant therapy in depressed women with breast cancer will attenuate increased intermediate endpoints of inflammation that contribute to the pathogenesis of depression, cognitive impairment, and cancer progression

Timeline

Start

2016-07

Primary completion

2018-07

Completion

2019-07

Drugs

Indications